(mobocertinib) TAKEDA
EXKIVITY is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. The recommended dosage of EXKIVITY is 160 mg orally once daily until disease progression or unacceptable toxicity.
Capsules: 40 mg
